A new nonsteroidal treatment for Duchenne muscular dystrophy (DMD) has been recommended in Europe for a conditional marketing authorisation to treat patients from the age of six. The drug, Duvyzat (givinostat), was approved by the US Food and Drug Administration in 2024. It was given a positive opinion by the European Medicines Agency on 25 April. Duvyzat is an oral suspension to be taken at the same time as corticosteroid, the current standard of care. The EMA is recommending the drug for patients who can still walk.
